Alpha 2.0
Login Register
» Articles » PMID: 35166673

Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice

Overview
Journal J Investig Allergol Clin Immunol
Specialty Allergy & Immunology
Date 2022 Feb 15
PMID 35166673
Authors
J C Miralles Lopez
R Andujar-Espinosa
F J Bravo-Gutierrez
M Castilla-Martinez
I Flores-Martin
M L Alemany-Frances
M J Pajaron-Fernandez
A Mora Gonzalez
J Valverde-Molina
V Perez-Fernandez
Affiliations
Soon will be listed here.
Citing Articles

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.

Padilla-Galo A, Moya Carmona I, Ausin P, Carazo Fernandez L, Garcia-Moguel I, Velasco-Garrido J Respir Res. 2023; 24(1):235.

PMID: 37770889 PMC: 10540395. DOI: 10.1186/s12931-023-02539-7.

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm: A Post Hoc Analysis from the ANANKE Study.

Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa M J Asthma Allergy. 2022; 15:1593-1604.

PMID: 36387835 PMC: 9661992. DOI: 10.2147/JAA.S383012.